iShares Neuroscience and Healthcare ETF
Price through Sep 30 · Flows through Sep 29. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET +$790K OVER THIS RANGE
Money is leaving — −$60K in net outflows over the past month, while the price has returned +1.7% so far this year. At 0.47% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | NEUNEWMARKET | 2.28% | $921.14 | +2.6% | ||
| 2 | BIIBBIOGEN | 4.78% | $222.82 | -1.4% | ||
| 3 | EWTXEDGEWISE THERAPEUTICS | 4.22% | $40.48 | -0.3% | ||
| 4 | PTCTPTC THERAPEUTICS | 4.35% | $64.13 | -1.0% | ||
| 5 | ARGXARGENX SE | 4.37% | $936.00 | -2.4% | ||
| 6 | NBIXNEUROCRINE BIOSCIENCES | 4.13% | $140.71 | -0.8% | ||
| 7 | ALKSALKERMES | 4.11% | $40.54 | +0.0% | ||
| 8 | SRRKSCHOLAR ROCK HOLDING | 4.00% | $46.16 | -4.5% | ||
| 9 | DNTHMAGENTA THERAPEUTICS INC | 3.74% | $88.32 | +0.3% | ||
| 10 | PRAXPRAXIS PRECISION MEDICINES | 3.70% | $286.91 | -1.5% | ||
| 11 | SUPNSUPERNUS PHARMACEUTICALS | 3.51% | $42.18 | -2.0% | ||
| 12 | ACADACADIA PHARMACEUTICALS | 3.35% | $19.89 | -1.3% | ||
| 13 | AXGNAXOGEN | 3.27% | $39.92 | -4.8% | ||
| 14 | XENEXENON PHARMACEUTICALS | 2.90% | $38.93 | +4.7% | ||
| 15 | DYNDYNE THERAPEUTICS | 3.10% | $15.82 | -1.8% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 54| 1 week | -1.4% |
| 1 month | -15.6% |
| 3 months | -14.2% |
| 6 months | +6.8% |
| YTD | +1.7% |
| 1 year | +22.3% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | −$7K |
| 1 month | −$60K |
| 3 months | +$2M |
| YTD | +$2M |
| 1 year | +$2M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 4.8% of the book; the top ten carry 41%. Spread across 75+ names, it behaves like roughly 35 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| DYN DYNE THERAPEUTICS | $8M | $2M |
| AXGN AXOGEN | $420,051 | $486,325 |
| ARGX ARGENX SE | $133,617 | $645,186 |
| PTCT PTC THERAPEUTICS | $313,359 | $425,676 |
| CAPR CAPRICOR THERAPEUTICS | $209,132 | $474,625 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IBRN on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -44bp on fee · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -44bp on fee · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -43bp on fee · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -43bp on fee · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -43bp on fee · +$412M in over the month | Head-to-head |